Method for establishing risk model for predicting intrahepatic cholestasis of pregnant women with maternal serum alpha fetoprotein

Abstract

The invention discloses a method for establishing a risk model for predicting intrahepatic cholestasis of pregnant women with maternal serum alpha fetoprotein. The method comprises the following steps: (1) dividing pregnant women into a case group and a control group according to the presence or absence of intrahepatic cholestasis in the gestation period, wherein the case group refers to a pregnant woman who is clinically diagnosed with intrahepatic cholestasis in the gestation period, and the control group refers to a pregnant woman who is randomly selected and has normal fetal development inthe same period; (2) detecting AFP levels of serum of two groups of pregnant women by adopting a time-resolved immunofluorescence method, constructing a risk calculation model by combining MOM valuesof the AFP with the prenatal age, and determining an optimal truncation value and an area AUC under the curve according to an ROC curve; (3) during detection, detecting the AFP level of the serum ofthe pregnant woman to be detected by adopting a time-resolved immunofluorescence method; and screening by using a risk calculation model constructed by combining the AFP with the prenatal age, and when the MOM value of the AFP of the serum of the pregnant woman to be detected is combined with the AUC predicted by the prenatal age modeling to exceed a set threshold value, judging that the fetus ofthe pregnant woman to be detected is intrahepatic cholestasis in the gestation period. The method has the beneficial effects that the MOM value of the AFP of the serum of the pregnant woman is combined with the pre-delivery age to screen the intrahepatic cholestasis in the gestation period, so that the method has high sensitivity and specificity and can become a new marker for predicting the intrahepatic cholestasis in the gestation period; the risk calculation model constructed by combining the MOM value of the AFP of the serum of the pregnant woman with the prenatal age has a great clinicalvalue in screening the intrahepatic cholestasis in the gestation period.

Description

Technical field [0001] The present invention relates to the field of medical testing, and is mainly a method for establishing a risk model for predicting intrahepatic cholestasis of pregnancy in maternal serum alpha-fetoprotein of pregnant women. Background technique [0002] Intrahepatic cholestasis of pregnancy (ICP) is a relatively benign cholestasis pathology of the liver that develops during the first and second trimesters of pregnancy. It is a liver-specific disease with an incidence of 0.02-2.40% [1 ], which is characterized by itchy skin and elevated serum bile acid levels [1-3]. Usually, ICP first appears in the form of itching at 28-30 weeks of pregnancy, especially at night. Nearly half of patients usually develop jaundice within 1-4 weeks after itching. Serum irisin levels in women with ICP Significantly higher [4]. The etiology of ICP is still unclear. Wei et al. [5] believe that HIF-1α, REDD1 and mTOR may play an important role in the response of the placenta of I...

AI Technical Summary

Problems solved by technology

However, the use of maternal serum PAPP-A, AFP, Freeβ-hCG and fetal NT to predict ICP is seldom reported.

Images